| CN

Advisory Center

News about imunopharm

Imunopharm Receives Clinical Trial Approval for CAR-T Drug to Treat Systemic Lupus Erythematosus 10-292024

China's First | Imunopharm Receives Clinical Trial Approval for CAR-T Drug in Metastatic Colorectal Cancer 10-122024

IM19 Clinical Trial Started 07-072020

Immunochina and Edigene announce that they will jointly develop an allogeneic CAR-T therapy for cancer 05-272020

Immunochina obtained approval of clinical trial for IM19 CAR-T cells treatment for refractory or relapse acute B-cell lymphoblastic leukemia 04-212020